TW202410893A - 用於治療t細胞淋巴瘤之結合治療 - Google Patents
用於治療t細胞淋巴瘤之結合治療 Download PDFInfo
- Publication number
- TW202410893A TW202410893A TW111142283A TW111142283A TW202410893A TW 202410893 A TW202410893 A TW 202410893A TW 111142283 A TW111142283 A TW 111142283A TW 111142283 A TW111142283 A TW 111142283A TW 202410893 A TW202410893 A TW 202410893A
- Authority
- TW
- Taiwan
- Prior art keywords
- cell lymphoma
- composition
- decitabine
- lymphoma
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263374137P | 2022-08-31 | 2022-08-31 | |
| US63/374,137 | 2022-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202410893A true TW202410893A (zh) | 2024-03-16 |
Family
ID=84359488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111142283A TW202410893A (zh) | 2022-08-31 | 2022-11-04 | 用於治療t細胞淋巴瘤之結合治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082286A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4580635A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025529240A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250053870A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022476674A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3266274A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025002312A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202410893A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024047394A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| LT4069254T (lt) * | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
-
2022
- 2022-11-04 JP JP2025513127A patent/JP2025529240A/ja active Pending
- 2022-11-04 TW TW111142283A patent/TW202410893A/zh unknown
- 2022-11-04 AU AU2022476674A patent/AU2022476674A1/en active Pending
- 2022-11-04 KR KR1020257007164A patent/KR20250053870A/ko active Pending
- 2022-11-04 CA CA3266274A patent/CA3266274A1/en active Pending
- 2022-11-04 WO PCT/IB2022/060652 patent/WO2024047394A1/en not_active Ceased
- 2022-11-04 EP EP22805975.4A patent/EP4580635A1/en active Pending
-
2023
- 2023-08-30 US US18/458,884 patent/US20240082286A1/en active Pending
-
2025
- 2025-02-26 MX MX2025002312A patent/MX2025002312A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4580635A1 (en) | 2025-07-09 |
| WO2024047394A1 (en) | 2024-03-07 |
| AU2022476674A1 (en) | 2025-04-17 |
| MX2025002312A (es) | 2025-04-02 |
| KR20250053870A (ko) | 2025-04-22 |
| JP2025529240A (ja) | 2025-09-04 |
| US20240082286A1 (en) | 2024-03-14 |
| CA3266274A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230364086A1 (en) | Combination therapies with ehmt2 inhibitors | |
| US12208141B2 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| US7479485B2 (en) | Method of treating arrhythmias | |
| CN115698014A (zh) | 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物 | |
| US9464093B2 (en) | Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer | |
| CN116113406B (zh) | Gas41抑制剂及其使用方法 | |
| RS64936B1 (sr) | Metodi lečenja hematoloških maligniteta korišćenjem 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benz il)amino-)izoindolin 1,3-diona | |
| JP2024542248A (ja) | Fgfr阻害剤とkras阻害剤を含む併用療法 | |
| US20240082286A1 (en) | Combination therapies for treatment of t-cell lymphomas | |
| US20250186451A1 (en) | Methods of treating cancer with iap antagonist compounds and combination therapies | |
| TW201725042A (zh) | 用於治療癌症及發炎病症之jak抑制劑與syk抑制劑之組合 | |
| CN1461219A (zh) | 非镇静巴比土酸盐化合物用作神经保护剂 | |
| JP2022502378A5 (cg-RX-API-DMAC7.html) | ||
| JP2014513104A (ja) | Pi3k/mtorのピリドピリミジノン阻害剤を用いたリンパ腫の治療方法 | |
| HK1219893A1 (zh) | 治療長qt綜合征的化合物和方法 | |
| JP2025525058A (ja) | ウイルス感染の処置のためのrock2阻害剤 | |
| AU2018379230A1 (en) | Treatment of RSV with combination product | |
| CN120112288A (zh) | 用于治疗肿瘤的药物组合、药物组合物及其用途 | |
| JP2024539641A (ja) | 癌の治療に使用するための変異retキナーゼの阻害剤 | |
| TW202608439A (zh) | 治療具有asxl1突變之個體之癌症的方法 | |
| HK40057712B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof | |
| HK1229250A1 (en) | Methods for treating cancers | |
| HK1229250B (en) | Methods for treating cancers |